Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of the drug Crofelemer in the
treatment of non-HIV patients with chronic idiopathic diarrhea; to determine the prevalence
of identifiable causes of chronic diarrhea in a non-HIV patients; to assess the diagnostic
yield, in terms of identification of treatable etiologies, of commercially available
diagnostic evaluations in adult, non-HIV patients with chronic idiopathic diarrhea, that is,
evaluate which tests, among the standard diagnostic tests commonly conducted as part of the
evaluation of chronic idiopathic diarrhea, are most likely to identify a treatable cause of
the diarrhea; and to analyze the relationship between chronic idiopathic diarrhea and
health-related quality of life and assess the impact of crofelemer treatment on
health-related quality of life.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborators:
Napo Pharmaceuticals, Inc. Prometheus Therapeutics and Diagnostics